Non-Daily Maintenance Dosing in Peanut Oral Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral immunotherapy (OIT) methods for peanut allergy may not sustain desensitization after therapy discontinuation, and daily dosing can lead to compliance and safety issues.
Innovation Solution
A non-daily maintenance phase dose regimen for peanut OIT, administered at frequencies such as every other day, twice a week, or once a week, for extended periods like 24 weeks to 108 weeks, to maintain desensitization and improve compliance and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily maintenance dosing is used in peanut OIT, then desensitization can be maintained, but patient compliance deteriorates and safety issues increase
Solution Approach 1:
The patent applies periodic action by transitioning from daily maintenance dosing to less frequent dosing schedules (e.g., every other day, twice weekly, or once weekly). This periodic dosing approach maintains desensitization effectiveness while significantly improving patient compliance and reducing safety concerns associated with daily administration.
2Reliability
If daily maintenance dosing is used in peanut OIT, then desensitization can be maintained, but safety deteriorates due to increased exposure frequency
Solution Approach 1:
The patent implements periodic action by reducing dosing frequency from daily to intermittent schedules (every other day, twice weekly, or once weekly). This approach maintains the therapeutic benefit of desensitization while reducing the cumulative exposure to peanut protein, thereby lowering the risk of allergic reactions and improving safety.
3Ease of operation
If therapy is discontinued after up-dosing phase, then treatment burden is reduced, but desensitization is lost
Solution Approach 1:
The patent applies periodic action by establishing a long-term maintenance phase with intermittent dosing schedules. This approach ensures sustained desensitization protection without requiring continuous daily therapy, thereby reducing treatment burden while maintaining reliability of desensitization over extended periods (24 weeks to 108 weeks or longer).
Data Source
AI summary
The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. The disclosure provides methods for treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase. In certain embodiments, the methods comprise non-daily administration to the subject of a maintenance phase dose. In certain embodiments, the methods comprise administering a maintenance phase dose for more than 24 weeks. In other embodiments, the disclosure provides methods for reducing the risk of an allergic adverse event in a subject receiving an oral immunotherapy dosage therapy.